看片视频

Invention 2019-033

A new amyloid-b antibody for the diagnosis of Alzheimer鈥檚 disease progression

听

A newly generated antibody was used as a biomarker for pre-symptomatic and early stages of Alzheimer鈥檚 at 看片视频

听

Market Need

Long before Alzheimer鈥檚 disease (AD) is clinically diagnosed, neurotoxic amyloid-b peptides form clumps in neuron junctions of the brain. These peptides accumulate into plaques, impair neural cell function, and are believed to contribute to overall cognitive decline. Unfortunately, these specific peptides do not reliably assess the disease stage or the likelihood of a patient progressing from mild cognitive impairment to clinical Alzheimer鈥檚. Without a clear biomarker, the opportunity for earlier intervention strategies is limited.

听

Technology Summary

With a newly generated monoclonal antibody specific to amyloid-b 34, the inventors were able to monitor amyloid beta clearance at earlier stages of the disease at higher reliability levels. As amyloid-b peptides are produced in the brain, scientists have recently used their clearance into cerebral spinal fluid as a measurement tool for Alzheimer鈥檚 progression. Compared to the classical Ab40/Ab42 ratio, elevated Ab34/Ab42 actually had a higher association rate with pre-symptomatic individuals that later developed Alzheimer鈥檚. Elevated Ab34 was also noted in patients with mild cognitive impairment, who later progressed to AD dementia. Based on these findings, the newly generated Ab34 monoclonal antibody could be very useful for diagnosing early Alzheimer鈥檚 disease.

听

Advantages

• Ab34 correlates with the average clearance of other neurotoxic peptides
• Levels of Ab34 are associated with Alzheimer鈥檚 disease progression
• The ratio of Ab34/Ab42 improves the ability to distinguish between patients who progressed from mild cognitive impairment to AD and those who did not

听

Patent Status

Filed US